Matches in SemOpenAlex for { <https://semopenalex.org/work/W92469905> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W92469905 endingPage "813" @default.
- W92469905 startingPage "811" @default.
- W92469905 abstract "Parenteral non-steroidal anti-inflammatory drugs (NSAIDs) are useful agents in the treatment of postoperative pain and other acute traumatic painful conditions such as fractures. Clinical trials with lornoxicam, an oxicam derivative, document its efficacy as a potent analgesic with excellent anti-inflammatory properties in painful and or/inflammatory conditions including postoperative pain and arthritic conditions. However, there is no documentation of the efficacy and tolerability of intravenous lornoxicam in Indian patients with acute painful conditions such painful traumatic conditions requiring hospitalisation and parenteral analgesics. The present study was undertaken to evaluate the efficacy and tolerability of intravenous lornoxicam in Indian patients with postoperative pain or other acute painful traumatic conditions requiring hospitalisation and parenteral analgesia in in-office practice conditions. In this multicentric, prospective, open, non-comparative phase IV, postmarketing surveillance study patients admitted in the nursing home for either postoperative pain or painful conditions requiring hospitalisation and parenteral analgesia were enrolled in the study after obtaining their informed consent. Of the 161 patients fulfilling the selection criteria, 148 met the selection criteria and were included in the efficacy analysis. Patients were treated with intravenous lornoxicam 8 mg twice or three times daily as required for up to 3 days. Efficacy variables included changes in severity of pain scores compared to baseline values, onset of pain relief and overall global efficacy. Tolerability was assessed through monitoring of treatment-emergent adverse events, physical examination, assessments of vital signs, and overall global assessment of tolerability. Results indicated that within 1 hour of administration of intravenous lornoxicam, the mean scores of pain severity were reduced by 39.46% and by 6 hours, there was a further 52% reduction in the mean scores. Therapy with intravenous lornoxicam was associated with a faster onset of action with 15.4% patients reporting pain relief within 10 minutes and 55.9% patients within 10 to 30 minutes. Overall, global assessment of efficacy was rated as good to excellent in 95.3% of the patients. Therapy with intravenous lornoxicam was well tolerated with only 5 patients reporting adverse events such as headache (n=3) and gastritis (n=1) of mild to moderate intensity but transient. Overall, global tolerability was rated as good to excellent in 98.4% of the total cases and fair in only 1.6% of the cases. In conclusion, the results of the present study indicate that intravenous lornoxicam is a potent NSAID with an optimal efficacy/toxicity ratio and thus could be a suitable therapeutic option in the management of patients with painful traumatic conditions requiring parenteral NSAIDs and hospitalisation." @default.
- W92469905 created "2016-06-24" @default.
- W92469905 creator A5009582379 @default.
- W92469905 creator A5011505228 @default.
- W92469905 creator A5059675698 @default.
- W92469905 date "2008-12-01" @default.
- W92469905 modified "2023-09-27" @default.
- W92469905 title "Lornoxicam efficacy in acute pain (LEAP) trial." @default.
- W92469905 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19370957" @default.
- W92469905 hasPublicationYear "2008" @default.
- W92469905 type Work @default.
- W92469905 sameAs 92469905 @default.
- W92469905 citedByCount "1" @default.
- W92469905 countsByYear W924699052016 @default.
- W92469905 crossrefType "journal-article" @default.
- W92469905 hasAuthorship W92469905A5009582379 @default.
- W92469905 hasAuthorship W92469905A5011505228 @default.
- W92469905 hasAuthorship W92469905A5059675698 @default.
- W92469905 hasConcept C126322002 @default.
- W92469905 hasConcept C197934379 @default.
- W92469905 hasConcept C2778375690 @default.
- W92469905 hasConcept C2779040406 @default.
- W92469905 hasConcept C2780820201 @default.
- W92469905 hasConcept C42219234 @default.
- W92469905 hasConcept C71924100 @default.
- W92469905 hasConceptScore W92469905C126322002 @default.
- W92469905 hasConceptScore W92469905C197934379 @default.
- W92469905 hasConceptScore W92469905C2778375690 @default.
- W92469905 hasConceptScore W92469905C2779040406 @default.
- W92469905 hasConceptScore W92469905C2780820201 @default.
- W92469905 hasConceptScore W92469905C42219234 @default.
- W92469905 hasConceptScore W92469905C71924100 @default.
- W92469905 hasIssue "12" @default.
- W92469905 hasLocation W924699051 @default.
- W92469905 hasLocation W924699052 @default.
- W92469905 hasOpenAccess W92469905 @default.
- W92469905 hasPrimaryLocation W924699051 @default.
- W92469905 hasRelatedWork W1510372753 @default.
- W92469905 hasRelatedWork W1987020767 @default.
- W92469905 hasRelatedWork W1999767203 @default.
- W92469905 hasRelatedWork W2035518831 @default.
- W92469905 hasRelatedWork W2077341628 @default.
- W92469905 hasRelatedWork W2093311839 @default.
- W92469905 hasRelatedWork W2168750649 @default.
- W92469905 hasRelatedWork W2177397691 @default.
- W92469905 hasRelatedWork W2342581101 @default.
- W92469905 hasRelatedWork W2619573154 @default.
- W92469905 hasRelatedWork W2788183575 @default.
- W92469905 hasRelatedWork W2897836849 @default.
- W92469905 hasRelatedWork W2911662957 @default.
- W92469905 hasRelatedWork W2914763243 @default.
- W92469905 hasRelatedWork W2949967744 @default.
- W92469905 hasRelatedWork W2981328654 @default.
- W92469905 hasRelatedWork W3037440813 @default.
- W92469905 hasRelatedWork W3203133616 @default.
- W92469905 hasRelatedWork W61021949 @default.
- W92469905 hasRelatedWork W2738184481 @default.
- W92469905 hasVolume "106" @default.
- W92469905 isParatext "false" @default.
- W92469905 isRetracted "false" @default.
- W92469905 magId "92469905" @default.
- W92469905 workType "article" @default.